Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy.

Current drug safety

Volumn 1, Issue 3, 2006, Pages 253-257

  Wirth, Thomas ^a   Hedman, Marja ^a   Mäkinen, Kimmo ^a   Manninen, Hannu ^a   Immonen, Arto ^a   Vapalahti, Matti ^a   Ylä Herttuala, Seppo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; LIPOSOME;

ADENOVIRUS; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE THERAPY; GENE VECTOR; GENETICS; GLIOMA; HUMAN; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PLASMID; RANDOMIZED CONTROLLED TRIAL;

ADENOVIRIDAE; AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; PLASMIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33747486473     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488606777934440     Document Type: Article

References (0)